Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGE NASDAQ:AVBP NASDAQ:CRSP NASDAQ:LEGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$83.49+2.9%$82.06$34.34▼$95.32$5.17B0.69917,756 shs149,523 shsAVBPArriVent BioPharma$27.47+2.8%$26.75$16.10▼$32.14$1.28B1.51477,731 shs137,179 shsCRSPCRISPR Therapeutics$50.90+1.1%$50.91$35.38▼$78.48$4.91B1.741.84 million shs488,372 shsLEGNLegend Biotech$29.64+0.9%$22.37$16.24▼$45.30$5.48B0.292.32 million shs718,054 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics0.00%+3.06%-5.20%+13.88%+105.57%AVBPArriVent BioPharma0.00%-1.15%-12.13%+14.72%+31.03%CRSPCRISPR Therapeutics0.00%+3.71%+3.24%-11.29%+36.63%LEGNLegend Biotech0.00%+8.86%+22.89%+50.62%+1.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$83.49+2.9%$82.06$34.34▼$95.32$5.17B0.69917,756 shs149,523 shsAVBPArriVent BioPharma$27.47+2.8%$26.75$16.10▼$32.14$1.28B1.51477,731 shs137,179 shsCRSPCRISPR Therapeutics$50.90+1.1%$50.91$35.38▼$78.48$4.91B1.741.84 million shs488,372 shsLEGNLegend Biotech$29.64+0.9%$22.37$16.24▼$45.30$5.48B0.292.32 million shs718,054 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics0.00%+3.06%-5.20%+13.88%+105.57%AVBPArriVent BioPharma0.00%-1.15%-12.13%+14.72%+31.03%CRSPCRISPR Therapeutics0.00%+3.71%+3.24%-11.29%+36.63%LEGNLegend Biotech0.00%+8.86%+22.89%+50.62%+1.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 2.78Moderate Buy$112.7335.03% UpsideAVBPArriVent BioPharma 2.91Moderate Buy$43.1356.99% UpsideCRSPCRISPR Therapeutics 2.53Moderate Buy$65.4728.63% UpsideLEGNLegend Biotech 2.67Moderate Buy$59.0099.06% UpsideCurrent Analyst Ratings BreakdownLatest AVBP, LEGN, APGE, and CRSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026AVBPArriVent BioPharma Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/20/2026LEGNLegend Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/18/2026LEGNLegend Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.005/13/2026LEGNLegend Biotech Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$62.00 ➝ $64.005/13/2026LEGNLegend Biotech TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$29.005/13/2026LEGNLegend Biotech Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$49.00 ➝ $48.005/13/2026CRSPCRISPR Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$50.00 ➝ $56.005/13/2026AVBPArriVent BioPharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$45.00 ➝ $43.005/11/2026CRSPCRISPR Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$76.005/6/2026LEGNLegend Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/6/2026CRSPCRISPR Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$80.00 ➝ $82.00(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$20.29 per shareN/AAVBPArriVent BioPharmaN/AN/AN/AN/A$6.96 per shareN/ACRSPCRISPR Therapeutics$3.51M1,398.66N/AN/A$18.81 per share2.71LEGNLegend Biotech$1.03B5.33N/AN/A$5.23 per share5.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$255.84M-$4.33N/AN/AN/AN/A-32.64%-31.25%8/10/2026 (Estimated)AVBPArriVent BioPharma-$166.31M-$3.47N/AN/AN/AN/A-48.98%-45.44%8/10/2026 (Estimated)CRSPCRISPR Therapeutics-$581.60M-$6.22N/AN/AN/A-13,856.54%-25.66%-20.39%8/3/2026 (Estimated)LEGNLegend Biotech-$296.80M-$0.68N/A17.64N/A-21.98%-24.92%-14.87%8/10/2026 (Estimated)Latest AVBP, LEGN, APGE, and CRSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026LEGNLegend Biotech-$0.02-$0.03-$0.01-$0.30$306.51 million$305.10 million5/11/2026Q1 2026APGEApogee Therapeutics-$1.0658-$1.06+$0.0058-$1.06N/AN/A5/11/2026Q1 2026AVBPArriVent BioPharma-$0.88-$0.96-$0.08-$0.96N/AN/A5/4/2026Q1 2026CRSPCRISPR Therapeutics-$1.2185-$1.28-$0.0615-$1.28$6.06 million$1.46 million3/31/2026Q1 2026CRSPCRISPR TherapeuticsN/A-$1.28N/A-$1.28N/A$1.46 million3/11/2026Q4 2025LEGNLegend Biotech-$0.17$0.01+$0.18-$0.16$310.21 million$306.30 million3/5/2026Q4 2025AVBPArriVent BioPharma-$0.87-$0.78+$0.09-$0.78N/AN/A3/2/2026Q4 2025APGEApogee Therapeutics-$1.05-$1.03+$0.02-$1.03N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/AAVBPArriVent BioPharmaN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A32.5932.59AVBPArriVent BioPharmaN/A13.9513.95CRSPCRISPR Therapeutics0.3217.9717.96LEGNLegend BiotechN/A2.132.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%AVBPArriVent BioPharma9.48%CRSPCRISPR Therapeutics69.20%LEGNLegend Biotech70.89%Insider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics24.30%AVBPArriVent BioPharma8.58%CRSPCRISPR Therapeutics4.30%LEGNLegend Biotech0.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9161.90 million46.86 millionOptionableAVBPArriVent BioPharma4046.58 million42.58 millionN/ACRSPCRISPR Therapeutics46096.45 million92.30 millionOptionableLEGNLegend Biotech2,965184.96 million184.92 millionOptionableAVBP, LEGN, APGE, and CRSP HeadlinesRecent News About These CompaniesLegend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 24 at 2:32 AM | americanbankingnews.comLegend Biotech to Showcase New CAR-T Data at ASCO 2026May 23 at 5:01 PM | theglobeandmail.comUBS Group AG Cuts Holdings in Legend Biotech Corporation Sponsored ADR $LEGNMay 22, 2026 | marketbeat.comLegend Biotech Announces Presentations at ASCO 2026May 21, 2026 | globenewswire.comAnalysts Are Bullish on Top Healthcare Stocks: Legend Biotech (LEGN), Krystal Biotech (KRYS)May 19, 2026 | theglobeandmail.comA China Tech Fund Opens a Biotech Position — Here's What That Actually SignalsMay 17, 2026 | aol.comAA China Tech Fund Opens a Biotech Position — Here's What That Actually SignalsMay 17, 2026 | fool.comLegend Biotech Corporation 2026 Q1 - Results - Earnings Call PresentationMay 15, 2026 | seekingalpha.comLegend Biotech (LEGN) Valuation After Strong Q1 2026 CARVYKTI Growth And Narrowing LossesMay 15, 2026 | finance.yahoo.comBarclays Reaffirms Their Buy Rating on Legend Biotech (LEGN)May 14, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Ovid Therapeutics (OVID) and Arvinas Holding Company (ARVN)May 14, 2026 | theglobeandmail.comBig Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category LeadersMay 14, 2026 | 247wallst.comAnalysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Tvardi Therapeutics (TVRD) and Organigram Global (OGI)May 14, 2026 | theglobeandmail.comLegend Biotech (LEGN) Trims Losses, Shares Climb Double-DigitsMay 12, 2026 | finance.yahoo.comLegend Biotech Corporation (LEGN) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comLegend Biotech (NASDAQ:LEGN) Announces Quarterly Earnings ResultsMay 12, 2026 | marketbeat.comLegend Biotech Q1 Earnings Call HighlightsMay 12, 2026 | marketbeat.comLegend Biotech Reports First Quarter 2026 Results and Recent HighlightsMay 12, 2026 | globenewswire.comIs Legend Biotech’s Expanded Scientific Board Quietly Redefining Its Long-Term CAR-T Strategy (LEGN)?May 5, 2026 | finance.yahoo.comIs Legend Biotech (LEGN) Pricing Reflect Recent Share Rebound Or Longer Term SetbacksMay 5, 2026 | finance.yahoo.comLegend Biotech (NASDAQ:LEGN) Sees Unusually-High Trading Volume - Here's WhyMay 5, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Alphabet’s Earnings Didn’t Just Beat—They Changed the StoryBy Ryan Hasson | April 30, 20263 Biotech Stocks That Could Benefit from the Patent CliffBy Chris Markoch | April 27, 2026AVBP, LEGN, APGE, and CRSP Company DescriptionsApogee Therapeutics NASDAQ:APGE$83.49 +2.33 (+2.87%) As of 11:51 AM EasternApogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.ArriVent BioPharma NASDAQ:AVBP$27.47 +0.74 (+2.77%) As of 11:51 AM EasternArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.CRISPR Therapeutics NASDAQ:CRSP$50.90 +0.54 (+1.07%) As of 11:51 AM EasternCRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Legend Biotech NASDAQ:LEGN$29.64 +0.27 (+0.92%) As of 11:51 AM EasternLegend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why BJ’s Wholesale Club Stock Could Be Ready for a Rebound After NVIDIA, Broadcom's Earnings Are Next—Here's What to Watch MarketBeat Week in Review – 05/18 - 05/22 Berkshire Sells Visa, Domino's, and Pool Corp: Should You Follow? Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Alphabet Just Unveiled Its Most Ambitious AI Lineup Yet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
